Literature DB >> 11398694

Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study.

A Druschky1, M Herkert, M Radespiel-Tröger, K Druschky, E Hund, C M Becker, M J Hilz, F Erbguth, B Neundörfer.   

Abstract

OBJECTIVE: First, to evaluate the role of typical intensive care-related conditions like sepsis, prolonged ventilation, drug effects and metabolic disorders in the pathogenesis of critical illness polyneuropathy (CIP); second, to investigate the possible significance of patient serum neurotoxicity assessed by an in vitro cytotoxicity assay with respect to CIP development.
DESIGN: Prospective study.
SETTING: Neurological intensive care unit. PATIENTS AND PARTICIPANTS: Twenty-eight patients who were on mechanical respiratory support for at least 4 days during a 21-month study period.
RESULTS: Diagnosis of CIP was established by clinical and electrophysiological examination in 16 (57%) of 28 patients. Patients were investigated on days 4, 8 and 14 of mechanical ventilation. Two of 16 CIP patients had clinical signs of polyneuropathy at initial examination. Factors that correlated significantly with the development of CIP were: the multiple organ failure score on day 8 of ventilation, the total duration of respiratory support, the presence of weaning problems and the manifestation of complicating sepsis and/or lung failure. The in vitro toxicity assay showed serum neurotoxicity in 12 of 16 CIP patients. Electrophysiological investigations yielded false positive results of the toxicity assay in six patients (not developing CIP) and false negative results in four patients (developing clinical and electrophysiological signs of CIP). Statistical analysis did not reveal a significant correlation between the diagnosis of CIP and the finding serum neurotoxicity.
CONCLUSION: The results support the hypothesis of a multi-factorial aetiopathogenesis of CIP. We observed serum neurotoxicity in the majority of CIP patients, indicating the possible involvement of a so far unknown, low-molecular-weight neurotoxic agent in CIP pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398694     DOI: 10.1007/s001340100890

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  18 in total

Review 1.  Persistent systemic inflammation in chronic critical illness.

Authors:  Christopher E Cox
Journal:  Respir Care       Date:  2012-06       Impact factor: 2.258

Review 2.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 3.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 4.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

5.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

6.  Facial nerve involvement in critical illness polyneuropathy.

Authors:  Mohan Gurjar; Afzal Azim; Arvind K Baronia; Banani Poddar
Journal:  Indian J Anaesth       Date:  2010-09

Review 7.  Critical illness myopathy and polyneuropathy.

Authors:  Shawn J Bird; Mark M Rich
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

8.  Predictive value for weakness and 1-year mortality of screening electrophysiology tests in the ICU.

Authors:  Greet Hermans; Helena Van Mechelen; Frans Bruyninckx; Tine Vanhullebusch; Beatrix Clerckx; Philippe Meersseman; Yves Debaveye; Michael P Casaer; Alexander Wilmer; Pieter J Wouters; Ilse Vanhorebeek; Rik Gosselink; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2015-08-13       Impact factor: 17.440

Review 9.  The incidence of intensive care unit-acquired weakness syndromes: A systematic review.

Authors:  Richard Td Appleton; John Kinsella; Tara Quasim
Journal:  J Intensive Care Soc       Date:  2014-12-18

Review 10.  Neuromuscular dysfunction acquired in critical illness: a systematic review.

Authors:  Robert D Stevens; David W Dowdy; Robert K Michaels; Pedro A Mendez-Tellez; Peter J Pronovost; Dale M Needham
Journal:  Intensive Care Med       Date:  2007-07-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.